Advanced search
Publication Cover
Journal of Medical Economics Volume 15, 2012 - Issue 4
Submit an article Journal homepage
706
Views
8
CrossRef citations to date
0
Altmetric
Original Article

Exenatide BID and liraglutide QD treatment patterns among type 2 diabetes patients in Germany

Lesley-Ann MillerEli Lilly and Company Indianapolis, INUSA
,
Chakkarin BurudpakdeeIMS Health Incorporated Falls Church, VAUSA
,
Anthony ZagarEli Lilly and Company Indianapolis, INUSA
,
Monali BhosleIMS Health Incorporated Falls Church, VAUSA
,
Matthew ReaneyEli Lilly and Company Windlesham, SurreyUKCorrespondence[email protected]
,
Vernon F. SchabertIMS Health Incorporated Falls Church, VAUSA
&
David BruhnEli Lilly and Company Indianapolis, INUSA
 show all
Pages 746-757 | Accepted 22 Mar 2012, Published online: 03 Apr 2012

References

  • World Health Organization. Diabetes Action Now. WHO and IDF, 2004. http://www.who.int/diabetes/actionnow/en/DANbooklet.pdf. Accessed March 1, 2012
  • International Diabetes Federation and Federation of European Nurses in Diabetes. Diabetes -- The Policy Puzzle: is Europe making progress? 2nd edn. IDF and FEND, 2008. http://www.idf.org/regions/europe/publications/diabetes-policy-audit. Accessed March 1, 2012
  • International Diabetes Federation. IDF Diabetes Atlas: prevalence estimates of diabetes mellitus (DM). 5th edn. IDF, 2011. http://www.diabetesatlas.org/content/prevalence-estimates-diabetes-mellitus-dm-2010. Accessed March 1, 2012
  • Hauner H, Bramlage P, Lösch C, et al. Overweight, obesity and high waist circumference: regional differences in prevalence in primary medical care. Dtsch Arztebl Int 2008;105:827-33
  • Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004;291:335-42
  • Gallwitz B. Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus. Treat Endocrinol 2005;4:361-70
  • Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203
  • Lind M, Jendle J, Torffvit O, et al. Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction. Prim Care Diabetes 2012;6:41-6
  • Jendle J, Nauck MA, Matthews DR, et al. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab 2009;11:1163-72
  • Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol 1993;46:1075-9
  • Byetta® [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc.; 2010
  • Victoza® [package insert]. Bagsvaerd, Denmark: Novo Nordisk A/S; 2011
  • Shapiro SS, Wilk MB. An analysis of variance test for normality (complete samples). Biometrika 1965;52:591-611
  • GLUCOPHAGE® [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2009
  • Defronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-100
  • Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27:2628-35
  • Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-91
  • Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomized, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39-47
  • McGill JB. Selecting among ADA/EASD tier 1 and tier 2 treatment options. J Fam Pract 2009;58(9 Suppl Treating):S26-34
  • Thong KY, Jose B, Sukumar N, et al. Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit. Diabetes Obes Metab 2011;13:703-10
  • Ryder REJ, Thong KY, Cull ML, et al. The Association of British Clinical Diabetologists (ABCD) nationwise exenatide and liraglutide audits. Poster. Association of British Clinical Diabetologists Meeting. London, England. November 10–11, 2011
  • Differences in response between exenatide and liraglutide in the Association of British Clinical Diabetologists (ABCD) nationwide audits. Abstract 00470. International Diabetes Federation World Diabetes congress. Dubai, United Arab Emirates. December 4–8, 2011

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.